Engineering Bacteria and Their Derivatives for Cancer Immunotherapy

Area of Science:

• Oncology
• Microbiology
• Immunotherapy

Background:

• Bacteria-based cancer therapy has gained attention since the discovery of "Cloey's toxin."
• A key challenge is balancing the safety and immunogenicity of bacterial treatments.
• Genetically modified bacteria and their components offer potential for improved cancer immunotherapy.

Purpose of the Study:

• To discuss the advantages of engineered bacteria and their derivatives for cancer immunotherapy.
• To highlight the challenges hindering the clinical translation of these bacterial-based approaches.

Main Methods:

• Review of engineered bacteria with removed virulence factors and integrated genetic elements.
• Analysis of bacterial derivatives: outer membrane vesicles (OMVs) and modified nanovesicles.
• Discussion of strategies to enhance antitumor immunity and improve safety profiles.

Main Results:

• Engineered bacteria can be modified to enhance their antitumor capabilities.
• Bacterial derivatives like OMVs and nanovesicles show potential for improved safety and immunogenicity.
• These approaches offer a promising avenue for developing novel cancer immunotherapies.

Conclusions:

• Engineered bacteria and their derivatives present unique advantages for cancer immunotherapy.
• Overcoming challenges related to safety, immunogenicity, and manufacturing is crucial for clinical application.
• Further research and development are necessary to translate these bacterial-based strategies into effective cancer treatments.